SKC Insights

Earli is transforming early cancer detection and treatment by bioengineering cancer cells to reveal and destroy themselves. Developed at the intersection of biology, engineering, and software, this platform answers the critical question — “Is it cancer? Y/N” — while enabling targeted therapeutic applications, paving the way for a new era in cancer care. 

Earli’s innovative work was recently featured in Medical Newspaper (Bosa), where CEO Cyriac Roeding shared insights on Korea and Japan’s leadership in early detection. Their groundbreaking advancements continue to push the field forward, an effort SKC is proud to support. 

Read more: Full Article on Bosa